Aachen-based startup Vivalyx secures €5.4m seed financing to improve donor organ quality

Aachen-based startup Vivalyx secures €5.4m seed financing to improve donor organ quality

Published: 01-05-2024 11:14:00 | By: Pie Kamau | hits: 890 | Tags:

Aachen-based organ vitality tech startup Vivalyx, has received an investment of €5.4 million led by TechVision Fonds (TVF) and Brightlands Venture Partners (BVP) in an oversubscribed seed financing round.

The team, led by Dr. Andreas Schumacher and Dr. Benedict Doorschodt is developing novel solutions to increase organ vitality with the aim to expand the number of organs available for life-saving transplantations. The capital raised will be used to finance the necessary clinical trials to achieve regulatory clearance and to start commercialization.

Andreas Schumacher, CEO, Vivalyx: "The financing round brings us a decisive step closer to bringing our products to market. We see great potential in our innovations to revolutionize the organ transplantation industry worldwide. We are pleased to have found investors who share our vision and back our mission."

Donor organ shortage remains a critical unmet medical need Patients and medical doctors are awaiting innovations in the field of organ transplantation. The statistics underpin the need for such innovations. The average waiting time for a donor kidney is up to eight years, and over a million patients worldwide are currently awaiting a donor organ. This shortage in donor organs is solvable by perfusing organs at body temperature: a method clinically proven but hardly scalable due to reliance on rare donor blood and its high costs. 

Vivalyx is introducing a patented solution surpassing this barrier for the first time, making perfusion at body temperature scalable. Their novel liquid Vivalyx Omnisol outperforms the efficacy of the blood-based benchmark in preclinical trials, is fully synthetic – eliminating blood-related concerns – and significantly cuts costs. Vivalyx Omnisol does not only work for perfusion at body-temperature, but is meant for all methods, cold and warm perfusion and static cold storage, with expected beneficial clinical outcomes. Thus, Vivalyx Omnisol will be the process- and cost-effective one stop solution for all preservation applications.

www.vivalyx.com
www.tvf.vc